320 related articles for article (PubMed ID: 22123498)
1. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
[TBL] [Abstract][Full Text] [Related]
2. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.
Trifirò G; Mokhles MM; Dieleman JP; van Soest EM; Verhamme K; Mazzaglia G; Herings R; de Luise C; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; van Camp G; Zanettini R; Sturkenboom MC
Drug Saf; 2012 Feb; 35(2):159-71. PubMed ID: 22204718
[TBL] [Abstract][Full Text] [Related]
3. Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey.
Wang V; Chao TH; Hsieh CC; Lin CC; Kao CH
Parkinsonism Relat Disord; 2015 Jan; 21(1):18-22. PubMed ID: 25457814
[TBL] [Abstract][Full Text] [Related]
4. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
Tran T; Brophy JM; Suissa S; Renoux C
CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
[TBL] [Abstract][Full Text] [Related]
5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
6. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.
Montastruc F; Moulis F; Araujo M; Chebane L; Rascol O; Montastruc JL
Eur J Clin Pharmacol; 2017 Jan; 73(1):99-103. PubMed ID: 27796464
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist use and the risk of heart failure.
Renoux C; Dell'Aniello S; Brophy JM; Suissa S
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):34-41. PubMed ID: 22109939
[TBL] [Abstract][Full Text] [Related]
8. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
9. Combination of two different dopamine agonists in the management of Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
[TBL] [Abstract][Full Text] [Related]
10. Risk of heart failure associated with dopamine agonists: a nested case-control study.
Hsieh PH; Hsiao FY
Drugs Aging; 2013 Sep; 30(9):739-45. PubMed ID: 23881697
[TBL] [Abstract][Full Text] [Related]
11. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists in Parkinson's disease.
Yamamoto M; Schapira AH
Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
[TBL] [Abstract][Full Text] [Related]
14. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
[TBL] [Abstract][Full Text] [Related]
15. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
[TBL] [Abstract][Full Text] [Related]
16. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
17. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease.
Valença GT; Glass PG; Negreiros NN; Duarte MB; Ventura LM; Mueller M; Oliveira-Filho J
Parkinsonism Relat Disord; 2013 Jul; 19(7):698-700. PubMed ID: 23611687
[TBL] [Abstract][Full Text] [Related]
18. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
[TBL] [Abstract][Full Text] [Related]
19. The link between non-ergot-derived dopamine agonists and heart failure: how strong is it?
Lockett K; DeBacker D; Cauthon KA
Consult Pharm; 2015 Mar; 30(3):136-40. PubMed ID: 25760663
[TBL] [Abstract][Full Text] [Related]
20. Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
Nissen T; Newman EJ; Grosset KA; Daghem M; Pal G; Stewart M; Odin P; Macphee GJ; Grosset DG
Scott Med J; 2012 Nov; 57(4):217-20. PubMed ID: 23002158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
